Skip to main content
Erschienen in: European Journal of Epidemiology 8/2007

01.08.2007 | Neuro-Epidemiology

Survival of Huntington’s disease patients in Serbia: longer survival in female patients

verfasst von: Tatjana Pekmezovic, Marina Svetel, Jelena Maric, Irena Dujmovic-Basuroski, Natasa Dragasevic, Milica Keckarevic, Stanka Romac, Vladimir S. Kostic

Erschienen in: European Journal of Epidemiology | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to estimate probability of survival of Huntington’s disease (HD) patients in Serbia as a function of CAG repeat length and selected demographic variables. This follow-up study was carried out at the Institute of Neurology, Clinical Centre of Serbia, Belgrade, 1982–2004. The study group consisted of 112 HD patients. The significant inverse correlation was found between CAG repeat length and age at onset of HD (r = −0.732, P = 0.001) and age at death (r = −0.760, P = 0.001). The cumulative probabilities of survival in a five, ten, fifteen, and twenty-years’ period were 90.9, 63.2, 10.3 and 4.5%, respectively. Higher survival probabilities were registered in female patients, as well as in those with older age at onset and lower number of CAG repeat length (≤46). The Cox regression analysis showed that significantly poorer outcome of HD in our population was related to younger age at onset (HR-hazard ratio = 1.9; P = 0.047), and larger CAG numbers (HR = 2.4; P = 0.071). The female sex was statistically significantly associated with longer survival (HR = 0.4; P = 0.007). These data might be of some importance for further exploration of natural history and prognosis of HD.
Literatur
1.
Zurück zum Zitat Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, Bylsma FW, Pearlson GD, Ross CA. Longitudinal change in basal ganglia volume in patients with Huntington s disease. Neurology 1997;48:394–7.PubMed Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, Bylsma FW, Pearlson GD, Ross CA. Longitudinal change in basal ganglia volume in patients with Huntington s disease. Neurology 1997;48:394–7.PubMed
2.
Zurück zum Zitat Brandt J, Bylsma FW, Gross R, Szine OC, Ranen N, Ross CA. Trinucleotide repeat length and clinical progression in Huntington disease. Neurology 1996;46:527–31.PubMed Brandt J, Bylsma FW, Gross R, Szine OC, Ranen N, Ross CA. Trinucleotide repeat length and clinical progression in Huntington disease. Neurology 1996;46:527–31.PubMed
3.
Zurück zum Zitat Cox DR. Regression models and life tables. J Royal Statist Soc 1972;34:187–220. Cox DR. Regression models and life tables. J Royal Statist Soc 1972;34:187–220.
4.
Zurück zum Zitat Culjkovic B, Stojkovic O, Vojvodic N, Svetel M, Rakic L, Romac S, Kostic VS. Correlation between triplet repeat expansion and computed tomography measures of caudate nuclei atrophy in Huntington’s disease. J Neurol 1999;246:1090–3.PubMedCrossRef Culjkovic B, Stojkovic O, Vojvodic N, Svetel M, Rakic L, Romac S, Kostic VS. Correlation between triplet repeat expansion and computed tomography measures of caudate nuclei atrophy in Huntington’s disease. J Neurol 1999;246:1090–3.PubMedCrossRef
5.
Zurück zum Zitat Foroud T, Gray J, Ivashina J, Conneally M. Differences in duration of Huntington’s disease based on age at onset. J Neurol Neurosurg Psychiatry 1999;66:52–6.PubMedCrossRef Foroud T, Gray J, Ivashina J, Conneally M. Differences in duration of Huntington’s disease based on age at onset. J Neurol Neurosurg Psychiatry 1999;66:52–6.PubMedCrossRef
6.
Zurück zum Zitat Furtado S, Suchoerrsky O, Rewcastle B, Graham L, Klimek M, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington disease. Ann Nerurol 1996;39:132–6.CrossRef Furtado S, Suchoerrsky O, Rewcastle B, Graham L, Klimek M, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington disease. Ann Nerurol 1996;39:132–6.CrossRef
7.
Zurück zum Zitat Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is unstable in Huntington’s disease chromosomes. Cell 1993;72:971–83. Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is unstable in Huntington’s disease chromosomes. Cell 1993;72:971–83.
8.
Zurück zum Zitat Illarioshkin SN, Igarashi S, Onodera O, Markova ED, Nikolskaya NN, Tanaka H, Chabrashwili TZ, Insorova NG, Endo K, Ivanova-Smoleskaya IA. Trinucleotide repeat length and rate of progression of Huntington’s disease. Ann Neurology 1994;36:630–5.CrossRef Illarioshkin SN, Igarashi S, Onodera O, Markova ED, Nikolskaya NN, Tanaka H, Chabrashwili TZ, Insorova NG, Endo K, Ivanova-Smoleskaya IA. Trinucleotide repeat length and rate of progression of Huntington’s disease. Ann Neurology 1994;36:630–5.CrossRef
9.
Zurück zum Zitat Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL. Age at onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet 1999;36:108–11.PubMed Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL. Age at onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet 1999;36:108–11.PubMed
10.
Zurück zum Zitat Koller WC, Barr A, Biary N. Estrogen treatment of dyskinetic disorders. Neurology 1982;32:547–9.PubMed Koller WC, Barr A, Biary N. Estrogen treatment of dyskinetic disorders. Neurology 1982;32:547–9.PubMed
11.
Zurück zum Zitat Kompoliti K. Estrogen and movement disorders. Clin Neuropharmacol 1999;22:318–26.PubMed Kompoliti K. Estrogen and movement disorders. Clin Neuropharmacol 1999;22:318–26.PubMed
12.
Zurück zum Zitat Mahant N, McCusker EA, Byth K, Graham S. Huntington’s disease. Clinical correlates of disability and progression. Neurology 2003;61:1085–92.PubMed Mahant N, McCusker EA, Byth K, Graham S. Huntington’s disease. Clinical correlates of disability and progression. Neurology 2003;61:1085–92.PubMed
13.
Zurück zum Zitat Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone in male patients with Huntington’s disease: relations to severity of illness and dementia. Ann Neurol 2005;57:520–5.PubMedCrossRef Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone in male patients with Huntington’s disease: relations to severity of illness and dementia. Ann Neurol 2005;57:520–5.PubMedCrossRef
14.
Zurück zum Zitat Mc Neil D. Epidemiological research methods. New York: John Wiley and Sons; 1996. Mc Neil D. Epidemiological research methods. New York: John Wiley and Sons; 1996.
15.
Zurück zum Zitat Persichetti F, Srinidhi J, Kanaley L, et al. Huntington’s disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. Neurobiol Dis 1994;1:159–66.PubMedCrossRef Persichetti F, Srinidhi J, Kanaley L, et al. Huntington’s disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains. Neurobiol Dis 1994;1:159–66.PubMedCrossRef
16.
Zurück zum Zitat Roos RA, Hermans J, Vegter-van der Vlis M, van Ommen GJ, Bruyn GW. Duration of illness in Huntington’s disease is not related to age at onset. J Neurol Neurosurg Psychiatry 1993;56:98–100.PubMed Roos RA, Hermans J, Vegter-van der Vlis M, van Ommen GJ, Bruyn GW. Duration of illness in Huntington’s disease is not related to age at onset. J Neurol Neurosurg Psychiatry 1993;56:98–100.PubMed
17.
Zurück zum Zitat Rosenblatt A, Abbott MH, Gourley LM, Troncoso JC, Margolis RL, Brandt J, Ross CA. Predictors of neuropathological severity in 100 patients with Huntington’s disease. Ann Neurol 2003;54:488–93.PubMedCrossRef Rosenblatt A, Abbott MH, Gourley LM, Troncoso JC, Margolis RL, Brandt J, Ross CA. Predictors of neuropathological severity in 100 patients with Huntington’s disease. Ann Neurol 2003;54:488–93.PubMedCrossRef
18.
Zurück zum Zitat Snell RF, Mac Millan JC, Cheadle JP, Fenton I, Lazarou LP, Daves P, MacDonald ME, Gusella JF, Harper PS, Show DJ. Relationship between trinucleotid repeat expansion and phenotypic variation in Huntington s disease. Nat Genet 1993;4:393–7.PubMedCrossRef Snell RF, Mac Millan JC, Cheadle JP, Fenton I, Lazarou LP, Daves P, MacDonald ME, Gusella JF, Harper PS, Show DJ. Relationship between trinucleotid repeat expansion and phenotypic variation in Huntington s disease. Nat Genet 1993;4:393–7.PubMedCrossRef
19.
Zurück zum Zitat Shulman LM. Is there a connection between estrogen and Parkinson’s disease? Parkinsonism and Relat Disord 2002;8:288–95. Shulman LM. Is there a connection between estrogen and Parkinson’s disease? Parkinsonism and Relat Disord 2002;8:288–95.
20.
Zurück zum Zitat Wheelock VL, Tempkin T, Marder K, Nonce M, Myers RH, Zhao H, Kayson E, Orme C, Shoulson I. Huntington Study Group. Predictors of nursing home placement in Huntington disease. Neurology 2003;60:998–1001.PubMed Wheelock VL, Tempkin T, Marder K, Nonce M, Myers RH, Zhao H, Kayson E, Orme C, Shoulson I. Huntington Study Group. Predictors of nursing home placement in Huntington disease. Neurology 2003;60:998–1001.PubMed
Metadaten
Titel
Survival of Huntington’s disease patients in Serbia: longer survival in female patients
verfasst von
Tatjana Pekmezovic
Marina Svetel
Jelena Maric
Irena Dujmovic-Basuroski
Natasa Dragasevic
Milica Keckarevic
Stanka Romac
Vladimir S. Kostic
Publikationsdatum
01.08.2007
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe 8/2007
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-007-9157-7

Weitere Artikel der Ausgabe 8/2007

European Journal of Epidemiology 8/2007 Zur Ausgabe